TABLE 3.
Association of VEGF Level with Overall Survival and Failure-Free Survival
Overall Survival | Failure-Free Survival | |||
---|---|---|---|---|
Hazard Ratio | Hazard Ratio | |||
Parameter | p | 95% CI | p | 95% CI |
Univariate Analysis | ||||
Log (VEGF Baseline) | 0.057 | 1.32 (0.99, 1.77) | 0.491 | 0.91 (0.71,1.18) |
Multivariate Analysisa | ||||
Log (Baseline VEGF) | 0.035 | 1.42 (1.03,1.97) | 0.843 | 0.97 (0.72, 1.32) |
Log (Baseline VEGF)-Log (VEGF Cycle 1) | 0.730 | 0.94 (0.64,1.37) | 0.722 | 0.93 (0.63 1.38) |
Performance (1–2 Vs. 0) | 0.084 | 1.58 (0.94,2.66) | 0.695 | 1.11 (0.67, 1.84) |
Age (≥65 Yr Vs. <65 Yr) | 0.077 | 1.59 (0.95,2.66) | 0.438 | 1.22 (0.74, 2.01) |
CI, confidence interval; VEGF, vascular endothelial growth factor.
Log baseline VEGF and Log (baseline VEGF)–Log (VEGF cycle 1) were forced into the final model with performance status, stage, age, treatment arm, sex, race, and histology as potential variables to be selected using stepwise algorithm with entry level of 0.10 and stay level of 0.10. Of 88 patients in the analysis, 78 patients were died; 85 failed (died or disease progressed).